The Council for Affordable Health Coverage (CAHC) is a broad-based alliance with a singular focus: bringing down the cost of health care for all Americans.
Small businesses need more affordable, flexible health coverage options. CAHC is leading the charge urging Congress to pass the CHOICE Act before year-end to expand coverage, lower costs and give employers and workers more choice.
cahc.net/resources/cahc-rall…
As @EricCantor takes the helm at @PhRMA, the stakes for patients couldn't be higher. Lowering drug costs requires real competition, transparency and policies that protect innovation and access, not government price-setting.
washingtonsun.com/congress/e…
Family caregivers deserve financial relief. CAHC joined a broad coalition of organizations in letters to the House and Senate urging passage of the bipartisan Lowering Costs for Caregivers Act, which helps families use tax-advantaged health accounts to cover caregiving expenses.
cahc.net/resources/cahc-join…
Nearly 60% of physicians now work for hospitals, up from just 25% a decade ago. As hospitals acquire more practices, patients face fewer choices and higher costs. In a new op-ed in the @DCJournal, CAHC's @jwhite_health looks at how to reverse this trend.
dcjournal.com/hospitals-are-…
Hospital costs are a leading driver of rising healthcare costs, leaving patients and taxpayers footing the bill.
In a new op-ed @jwhite_health outlines solutions Congress can advance to rein in hospital costs & make care more affordable.
dcjournal.com/hospitals-are-…
My latest in @InsideSourcesDC. Hospitals Are Increasing Costs; Congress Should Stop Rewarding Them.
Most recent policy choices restrict supply or juice demand. This increases prices and costs for consumers. To lower premiums and out of pocket costs, Congress should reward efficiency and increase supply. @C4AHCdcjournal.com/hospitals-are-…
If you're attending the @IVI_health Whole Health Policy Summit, don't miss CAHC's @jwhite_health @ 11:30. Joel and his fellow panelists will discuss how policy, measurement & incentives can better reflect outcomes that matter to patients & families.
As the midterms give way to a new Congress, CAHC's survey offers a cautionary lesson: cozying up to insurers carries political risks. Addressing rising healthcare costs means holding insurers accountable, not protecting their interests.
dailycaller.com/2026/11/05/r…
.@DrOzCMS at today's DOL event highlighting new PBM transparency rules & potential savings for Americans. But more must be done. Congress should ban spread pricing & fix Medicare Part D. Insurers shouldn't own PBMs, pharmacies, doctors & imaging centers. Patients before monopolies.
CAHC's @jwhite_health will join @IVI_health's Whole Health Policy Summit on Nov 10! He & his fellow panelists will discuss how policy, measurement & incentives can better reflect outcomes that matter to patients & families. REGISTER: valueresearch.org/events/202…
Employees are watching more of their hard-earned wages disappear into premiums and deductibles. Insurers need to answer for why coverage costs so much and delivers so little. nytimes.com/2026/10/22/busin…
In case you missed it, @WaysandMeansGOP held a hearing earlier this year on the impact of rising health care costs on patients and families.
We need serious reform of health insurers who put profits above patients.
Patients benefit when pharmaceutical companies compete to develop better, more affordable treatments. The COINS Act should not create new barriers to innovation and competition. More treatment options, greater patient choice, and lower healthcare costs should be the goal.
Competition drives innovation, expands patient choice, and helps lower healthcare costs. But proposed COINS Act regulations could restrict investments in promising new medicines, creating more government barriers to the development of lifesaving treatments.
America's pharmaceutical industry leads the world in innovation because it has access to global scientific breakthroughs. Restricting international biotech partnerships risks slowing drug development, limiting patient access to new treatments, and driving up costs. Patients deserve better.
The COINS Act could create new barriers to global biotech partnerships, threatening America's leadership in pharmaceutical innovation. Policymakers must balance national security with the need to keep lifesaving treatments moving from research labs to patients.statnews.com/2026/10/23/new-…
The COINS Act could create new barriers to global biotech partnerships, threatening America's leadership in pharmaceutical innovation. Policymakers must balance national security with the need to keep lifesaving treatments moving from research labs to patients.statnews.com/2026/10/23/new-…